Identification of Genipin as a Potential Treatment for Type 2 Diabetes
| dc.contributor.author | Wu, Yajun | en |
| dc.contributor.author | Wang, Yao | en |
| dc.contributor.author | Liu, Dongmin | en |
| dc.date.accessioned | 2023-02-10T14:41:18Z | en |
| dc.date.available | 2023-02-10T14:41:18Z | en |
| dc.date.issued | 2023-01-21 | en |
| dc.date.updated | 2023-02-10T14:28:21Z | en |
| dc.description.abstract | The prevalence of type 2 diabetes (T2D) has been rising dramatically in many countries around the world. The main signatures of T2D are insulin resistance and dysfunction of β-cells. While there are several pharmaceutical therapies for T2D, no effective treatment is available for reversing the functional decline of pancreatic β-cells in T2D patients. It has been well recognized that glucagon-like peptide-1 (GLP-1), which is an incretin hormone secreted from intestinal L-cells, plays a vital role in regulating glycemic homeostasis via potentiating glucose-stimulated insulin secretion and promoting β-cell function. We found that genipin, a natural compound from Elli, can directly target intestinal L-cells, leading to the secretion of GLP-1. Incubation of the cells with genipin elicited a rapid increase in intracellular Ca<sup>2+</sup>. Inhibition of PLC ablated genipin-stimulated Ca<sup>2+</sup> increase and GLP-1 secretion, suggesting that genipin-induced GLP-1 release from cells is dependent on the PLC/Ca<sup>2+</sup> pathway. In vivo, acute administration of genipin stimulated GLP-1 secretion in mice. Chronically, treatment with genipin via oral gavage at 50 mg/kg/day for 6 weeks reversed hyperglycemia and insulin resistance in high-fat-diet (HFD)-induced obese mice. Moreover, genipin alleviated the impaired lipid metabolism and decreased lipid accumulation in the liver of obese mice. These results suggest that naturally occurring genipin might potentially be a novel agent for the treatment of T2D and diet-induced fatty liver disease. | en |
| dc.description.version | Published version | en |
| dc.format.mimetype | application/pdf | en |
| dc.identifier.citation | Wu, Y.; Wang, Y.; Liu, D. Identification of Genipin as a Potential Treatment for Type 2 Diabetes. Int. J. Mol. Sci. 2023, 24, 2131. | en |
| dc.identifier.doi | https://doi.org/10.3390/ijms24032131 | en |
| dc.identifier.uri | http://hdl.handle.net/10919/113770 | en |
| dc.language.iso | en | en |
| dc.publisher | MDPI | en |
| dc.rights | Creative Commons Attribution 4.0 International | en |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | en |
| dc.subject | genipin | en |
| dc.subject | type 2 diabetes | en |
| dc.subject | GLP-1 | en |
| dc.subject | L-cells | en |
| dc.subject | insulin resistance | en |
| dc.subject | lipid accumulation | en |
| dc.subject | mice | en |
| dc.title | Identification of Genipin as a Potential Treatment for Type 2 Diabetes | en |
| dc.title.serial | International Journal of Molecular Science | en |
| dc.type | Article - Refereed | en |
| dc.type.dcmitype | Text | en |